Characteristics and prospective 2-year follow-up of children with pulmonary arterial hypertension in France  by Fraisse, Alain et al.
Archives of Cardiovascular Disease (2010) 103, 66—74
CLINICAL RESEARCH
Characteristics and prospective 2-year
follow-up of children with pulmonary
arterial hypertension in France
Caractéristiques et suivi prospectif sur deux ans d’enfants atteints
d’hypertension artérielle pulmonaire en France
Alain Fraissea, Xavier Jaisb, Jean-Marc Schleichc,
Sylvie di Filippod, Pascale Maragnèse,
Maurice Beghetti f, Virginie Gressing, Michel Voisinh,
Claire Dauphin i, Pierre Clersonj,
Franc¸ois Godartk, Damien Bonnet l,∗
a Hôpital de la Timone, 13000 Marseille, France
b Hôpital Antoine-Béclère, 92140 Clamart, France
c Hôpital Pontchaillou, 35000 Rennes, France
d Hôpital Louis-Pradel, 69003 Lyon, France
e Hôpital Côte-de-Nacre, 14000 Caen, France
f Children’s Hospital, Geneva, Switzerland
g Actelion Pharmaceuticals France, 75001 Paris, France
h Hôpital Arnaud-de-Villeneuve, 34000 Montpellier, France
i Hôpital Gabriel-Montpied, 63000 Clermont-Ferrand, France
j Orgamétrie, 59100 Roubaix, France
k Hôpital cardiologique, 59000 Lille, France
l Centre de référence malformations cardiaques congénitales complexes-M3C,
université Paris-Descartes, hôpital Necker—Enfants-Malades,
AP—HP, 149, rue de Sèvres, 75015 Paris, FranceReceived 21 October 2009; received in revised form 5 December 2009; accepted 7 December
2009
Available online 11 February 2010
KEYWORDS
Pulmonary arterial
hypertension;
Summary
Background.— Limited data are available describing paediatric pulmonary arterial hyperten-
sion.
∗ Corresponding author.
E-mail address: damien.bonnet@nck.aphp.fr (D. Bonnet).
1875-2136/$ — see front matter © 2010 Elsevier Masson SAS. All rights reserved.
doi:10.1016/j.acvd.2009.12.001
Follow-up of French children with
Congenital heart
defect;
Paediatric;
Epidemiology;
Quality of life
MOTS CLÉS
Hypertension
artérielle
pulmonaire ;
Cardiopathie
congénitale ;
Pédiatrie ;
épidémiologie ;
Qualité de vie
pulmonaire concomitante d’une cardiopathie congénitale a été identiﬁé et ressemble à une
hypertension artérielle pulmonaire idiopathique. Les associations de traitements spéciﬁques
tribué à la stabilité de la maladie et à une meilleure survie.
Tous droits réservés.de l’HTAP peuvent avoir con
© 2010 Elsevier Masson SAS.Abbreviations
CI conﬁdence interval
CHQ-PF50 Child Health Questionnaire-Parent Form 50
IPAH idiopathic PAH
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Aims.— To characterize the epidemiology, management and impact on quality of life and
outcome of paediatric pulmonary arterial hypertension, excluding persistent pulmonary hyper-
tension of the newborn and pulmonary arterial hypertension caused by congenital heart disease.
Methods.— In this multicentre study, children with pulmonary arterial hypertension were
included and followed prospectively for two years at 21 referral centres in France. WHO
functional class, 6-minute walk distance and quality of life (CHQ-PF50 questionnaire) were
evaluated.
Results.— Fifty children were included with a mean age of 8.9± 5.4 years from May 2005 until
June 2006. The estimated prevalence for pulmonary arterial hypertension was 3.7 cases/million.
Patients had idiopathic pulmonary arterial hypertension (60%), familial pulmonary arterial
hypertension (10%), pulmonary arterial hypertension associated with, but not caused by, con-
genital heart disease (24%), pulmonary arterial hypertension associated with connective tissue
disease (4%) or portal hypertension (2%). During follow-up, the combination of pulmonary arte-
rial hypertension-speciﬁc therapies was increasingly prescribed (44% patients versus 22% at
inclusion). Patients remained stable regarding clinical status, 6-minute walk distance and qual-
ity of life. Survival estimates after one and two years were 86% (95% CI 76, 96) and 82% (95% CI
71, 93), respectively.
Conclusions.— In children, idiopathic/familial pulmonary arterial hypertension accounts for
the majority of cases. A speciﬁc pulmonary arterial hypertension group in conjunction with
congenital heart disease can be identiﬁed that resembles patients with idiopathic pulmonary
arterial hypertension. Combined pulmonary arterial hypertension-speciﬁc therapies may have
contributed to disease stability and favourable survival.
© 2010 Elsevier Masson SAS. All rights reserved.
Résumé
Justiﬁcation.— Les données décrivant l’hypertension artérielle pulmonaire chez l’enfant sont
peu nombreuses.
Objectifs.— L’objectif a été de caractériser l’épidémiologie, la prise en charge, l’impact sur
la qualité de vie et les conséquences de l’hypertension artérielle pulmonaire de l’enfant en
excluant les patients avec une hypertension pulmonaire persistante du nouveau-né et ceux
dont l’hypertension artérielle pulmonaire était causée par une cardiopathie congénitale.
Méthodes.— Dans cette étude multicentrique, des enfants atteints d’hypertension artérielle
pulmonaire ont été inclus et suivis prospectivement pendant deux ans dans 21 centres franc¸ais.
La classe fonctionnelle OMS, la distance de marche de sixminutes et la qualité de vie (ques-
tionnaire CHQ-PF50) ont été évaluées.
Résultats.— Cinquante enfants ont été inclus avec un âge moyen de 8,9± 5,4 ans de mai 2005 à
juin 2006. La prévalence de l’hypertension artérielle pulmonaire a été estimée à 3,7 cas/million.
Les patients avaient une hypertension artérielle pulmonaire idiopathique (60 %), familiale
(10 %), associée avec une cardiopathie congénitale qui n’était pas la cause de l’hypertension
artérielle pulmonaire (24 %), associée à une connectivite (4 %) ou à une hypertension portale
(2 %). Pendant le suivi, le nombre d’associations de médicaments spéciﬁques de l’hypertension
artérielle pulmonaire prescrits a augmenté (44 % patients contre 22% à l’inclusion). Les patients
sont restés stables en ce qui concerne leur état clinique, test de marche de sixminutes et qual-
ité de vie. La survie à un et deux ans a été estimée à 86% (intervalle de conﬁance à 95% :
[76,96]) et 82 % (intervalle de conﬁance à 95% : [71,93]).
Conclusions.— Chez l’enfant, dans la majorité des cas, les hypertensions artérielles pul-
monaires sont idiopathiques / familiales. Un groupe spéciﬁque d’hypertension artérielleAH-CHD PAH associated with congenital heart disease
UALIN quality of life
HO World Health Organization
MWD 6-minute walk distance
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ntroduction
AH is characterized by a progressive increase in pulmonary
ascular resistance leading to right ventricular failure [1].
he impact on quality of life is substantial and the prognosis
oor [2,3]. The natural history of PAH in adults was described
nitially by a national registry conducted in the United
tates in the early 1980s, which included patients with IPAH
ollowed for up to ﬁve years [3]. Following subsequent signif-
cant advances in the development of PAH-speciﬁc therapies
e.g., prostacyclin, endothelin receptor antagonists, and
ype 5 phosphodiesterase inhibitors), a multicentre registry
as initiated in France, in 2002, to collect data on adult
atients with PAH treated in the modern era, and to doc-
ment the evolution of PAH during a 3-year follow-up [4].
owever, no such multicentre studies have been performed
n children and the current understanding of the epidemi-
logy and natural course of paediatric PAH is consequently
imited.
Adults and children with PAH present with the same
istopathological lesions [5] and the same abnormalities
f vascular and endothelial homeostasis, including imbal-
nce of prostacyclin and thromboxane A2 [6] and abnormal
ulmonary clearance of endothelin-1 [7]. The spectrum
f associated conditions, clinical presentation, and factors
nﬂuencing survival, however, may differ between adults and
hildren. Although limited data are available on the clinical
esponses of paediatric PAH patients, children with severe
AH are currently treated with similar clinical strategies
o those applied to adults [8]. Treatment goals for pae-
iatric patients with PAH may require speciﬁc adaptations
f adult treatments in order to meet a different set of
ractical, social and therapeutic challenges [9]. There are
urrently, however, insufﬁcient data to inform treatment
bjectives and decisions. This prospective, multicentre,
on-interventional study was therefore initiated to investi-
ate the speciﬁc epidemiology of paediatric PAH. This study
lso examined the medical management of paediatric PAH
n the current treatment era and the impact on quality of
ife and outcome during a 2-year follow-up period.
ethods
tudy design
his multicentre, prospective, non-interventional study was
nitiated in May 2005 and was based on a previously
escribed method [10]. Enrolled patients either had a known
iagnosis of PAH before the beginning of the study or were
iagnosed during the recruitment period (cross-sectional
hase), from May 2005 until June 2006. All enrolled patients
ere followed prospectively for two years (longitudinal
hase). The protocol did not impose any procedures or
herapies. Written, informed consent was obtained from
atients or guardians before data collection.tudy patients
atients aged between 28 days and 18 years were included.
atients with PAH-CHD were only included if the increase
n pulmonary vascular resistance could be considered
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nrelated to the congenital heart defect (i.e. children
ith PAH related to an atrial septal defect with increased
ulmonary vascular resistance from birth or a transpo-
ition of the great arteries associated with PAH after an
rterial switch operation). These patients were referred
o as patients with PAH in conjunction with CHD. Patients
ith an evolving defect, which could lead to increased
ulmonary vascular resistance (either left-to-right shunt
r left heart obstructive defect), were excluded. Patients
ith persistent pulmonary hypertension of the newborn
ere also excluded because their disease differs from other
AH aetiologies in terms of natural history and treatment.
iagnosis of PAH
iagnosis of PAH was established using either right heart
atheterization or Doppler echocardiography following the
uropean Society of Cardiology guidelines [11]. Patients
ere considered responsive to vasodilator testing if inhaled
itric oxide during right heart catheterization-induced
eductions in mean pulmonary arterial pressure greater
han 10 mmHg, leading to a value less than 40 mmHg, with
ncreased or unchanged cardiac output.
atient characteristics at inclusion and study
ssessments
AH history included date of ﬁrst presentation, date of
iagnosis and World Health Organization functional class at
iagnosis. Age, height, weight and functional signs were doc-
mented at study inclusion and a complete physical and
ardiac examination was performed.
WHO functional class and exercise capacity measured
y the 6MWD in patients older than seven years [12] were
etermined at inclusion and at six months, one year and
wo years. Haemodynamic parameters were collected at
nclusion and at six months, one year and two years. Last
ssessment was deﬁned as the latest available assessment
erformed at month 6, Year 1 or 2.
Assessment of quality of life was collected at inclusion,
ne year and two years, using parent-administered versions
f the most appropriate questionnaires for each age group.
or children aged less than ﬁve years, analyses from the
UALIN [13] and Autoquestionnaire Enfant Image (AUQUEI)
nstruments [14] planned per protocol [10] were not pre-
ented due to the small number of patients. For children
ver ﬁve years, results from the Child Health Questionnaire
Parent. Form 50 (CHQ-PF50) questionnaire [15] at inclu-
ion were compared with those of standard (n = 73; age range
—7 years) [16] and asthmatic (n = 74; age range 5—12 years)
17] paediatric reference cohorts.
tatistical analysis
uantitative variables are described as mean± SD or median
range), when appropriate. For analytical comparisons
etween two groups of normally distributed quantitative
ata, Student’s t-test was performed; in case of small
amples of patients or not normally distributed variables,
he non-parametric Wilcoxon’s test was used. For multiple
omparisons of quantitative data, analysis-of-variance or
on-parametric tests were used. Qualitative variables are
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described using frequencies and percentages. For analyti-
cal comparisons between two groups of matched qualitative
data, the Mc Nemar’s test was performed. A p value less than
0.05 was considered signiﬁcant. Statistical analyses were
performed using SAS software (version 8; SAS Institute, Cary,
NC).
Patient height and weight were compared with average
values for French children of the same age. Delayed growth
was deﬁned as height or weight at least twice the standard
deviation below the mean.
Prevalence of PAH was calculated as the ratio between
the number of enrolled patients and the number of persons
aged between 28 days and 18 years in the French popula-
tion (excluding overseas territories) in 2006, derived from
public data provided by the Institut national d’études démo-
graphiques population census [18].
Survival, assessed from study inclusion until death/data
cut-off date, was summarized using Kaplan-Meier estimates
and 95% conﬁdence interval (CI) of the event-free survival
at relevant time points.
Results
Fifty patients (35 with a diagnosis established before study
initiation) were included from 21 referral centres with a
widespread geographical distribution in France [10]. Five
participating centres did not recruit patients. Patients were
followed for a median duration of 23.4 months (range
0.1—31).
Diagnosis of PAH
Diagnosis of PAH was conﬁrmed using right heart catheter-
ization in 43 of 50 patients (86%) and was performed a
median 2.7 years before study initiation (range 0—15 years).
The mean pulmonary artery pressure was 59± 18 mmHg
and the cardiac index was 3.9± 1.8 Ll/min/m2. Four of 35
patients evaluated (11%) were responsive to nitric oxide.
C
T
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Table 1 Patient characteristics at study inclusion (n = 50).
Characteristic
Boys / girls
Age, years
Weight, kg
Aetiology of pulmonary arterial hypertension
Idiopathic
In conjunction with CHD
Familial
Connective tissue disease
Portal hypertension
Haemodynamics
Mean pulmonary artery pressure, mmHg (n = 43)
Cardiac index, L/min/m2 (n = 30)
Indexed pulmonary vascular resistance, Wood units.m2 (n = 2
Acute vasoreactivity
WHO FC I, II, III, IV (n = 46)a
Values are number (percentage) of patients or mean± standard deviat
a Four patients did not have an inclusion assessment (including three p69
he remaining seven patients had the diagnosis conﬁrmed
y Doppler echocardiography; their mean calculated sys-
olic pulmonary arterial pressure using maximum velocity
f tricuspid regurgitation was 87± 18 mmHg.
revalence of PAH
he overall prevalence of PAH (excluding persistent pul-
onary hypertension of the newborn and PAH caused by
HD) in paediatric patients in 2005 was estimated to be at
east 3.7 cases per million. The prevalence of idiopathic IPAH
n paediatric patients was estimated to be at least 2.2 cases
er million.
atient demographics and disease
haracteristics at inclusion
he characteristics at inclusion of the 50 patients are sum-
arized in Table 1. The male to female ratio was 1.1:1.0.
atients were 4.4± 4.5 years at ﬁrst symptoms and 5.1± 4.8
t diagnosis. They most frequently had IPAH (60%). PAH asso-
iated with but not caused by CHD was encountered in 24%
f the patients (Table 2).
Low weight and height were reported in 12 (24%) and
ight (16%) patients, respectively and nine patients (18%)
ad a history of premature birth, deﬁned as less than 36
eeks of gestation. Two patients developed PAH shortly after
one marrow transplantation, a procedure which can be
ssociated with chemoradiation-induced lung injury [19].
oth of these patients were responsive to calcium chan-
el inhibitors. One patient had an astrocytoma treated with
hemotherapy; no link with the PAH diagnosis was consid-
red. Two patients had major digestive surgery.linical symptoms
he most frequently reported clinical symptoms were dys-
noea and fatigue whereas signs of right heart failure
26 (52) / 24 (48)
8.9± 5.4 (0.4—18)
28.3± 17.9 (4—70)
30 (60)
12 (24)
5 (10)
2 (4)
1 (2)
59± 18
3.8± 1.8
9) 20± 19
4 (11)
8, 25, 12, 1 (17, 54, 26, 2)
ion (range).
atients who died during the ﬁrst month of follow-up).
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Table 2 Characteristics of patients with PAH in conjunction with CHD.
CHD/surgery Age at diagnosis/ inclusion (years) Premature Weight (kg) WHO FC at inclusion
ASD/SC 5.4 / 13.8 — 41.0 II
ASD/SC 4.1 / 7.5 + 17.5 III
ASD/SC 1.1 / 6.9 — 20.0 III
PDAa/no 0.5 / 05 + 6.2 —
PDA/SC 0.8 / 16.3 — 42.0 II
PDA/SC 4.2 / 10.8 — - —
TGA/ASO 0.1 / 9.4 — 20.0 II
TGA/ASO 0.2 / 0.4 — 6.9 I
TGA/ASO 0.9 / 13.3 — 28.0 III
TGA/ASO 2.0 / 7.8 — 26.5 II
TGA/ASO 0.3 / 1.5 — 4.2 I
Scimitar syndrome/no 0 (7 days)b / 7 + 16.0 II
a With CHARGE syndrome and no signiﬁcant left-to-right shunt.
b Without persistent pulmonary arterial hypertension of the newborn.
ASD, atrial septal defect; ASO, arterial switch operation; PDA, patent ductus arteriosus; SC, surgical closure; TGA, transposition of the
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(great arteries; WHO FC, Word Health Organization functional clas
hepatomegaly) were rare (Table 3). At the last assessment,
o signiﬁcant changes were observed except for cyanosis
ith exercise.
HO functional class, 6MWD and
aemodynamics
f 50 patients, 44 were evaluated for WHO functional class
t both inclusion and last assessment (40 patients had a 2-
ear assessment, two had their last assessment at one year
nd two at six months). At the last assessment, 11 patients
25%) had improved from inclusion by at least one class (95%
I 12, 38), and 12 patients (27%) had worsened by at least
ne class (95% CI 14, 40).
The 6MWD performed for children over seven years of age
mproved non-signiﬁcantly from 421± 65min at inclusion
n = 22) to 448± 108min at last assessment (n = 25; p = 0.07).
d
a
q
P
Table 3 Changes between inclusion and last assessment.
Parameter
Clinical parameters
Dyspnoea
Fatigue
Cyanosis with exercise
Syncope
Chest pain
Hepatomegaly
Haemodynamic parameters
Mean pulmonary artery pressure, mmHg
Cardiac index, L/min/m2
Indexed pulmonary vascular resistance, Wood units.m2
Values are number (percentage) of patients or mean± standard deviat
a p = 0.02.Thirteen patients had a haemodynamic evaluation by
ight heart catheterization at inclusion and last assessment.
his evaluation detected no signiﬁcant changes in haemody-
amic parameters (Table 3).
mpact of PAH on scholarship and quality of
ife
t inclusion, from a subpopulation of 40 patients over three
ears of age, 29 (81%) were attending regular school, of
hich three were experiencing learning disabilities and
even (19%) received tuition in a specialized establishment
the educational establishment was unspeciﬁed for four chil-
ren). These percentages were not different at the last
ssessment.
The majority of quality-of-life scores from the CHQ-PF50
uestionnaire were reduced for paediatric patients with
AH compared with the standard and asthmatic paediatric
Inclusion Last assessment
(n = 50) (n = 44)
38 (76%) 35 (80%)
33 (72%) 25 (57%)
8 (16%) 13 (30%)a
5 (11%) 3 (7%)
3 (7%) 4 (9%)
3 (6%) 5 (11%)
(n = 13) (n = 13)
59.7± 14.7 59.6± 18.2
3.0± 1.3 3.1± 1.3
10.6± 6.0 7.6± 4.3
ion.
Follow-up of French children with PAH 71
Figure 1. Comparison of CHQ-PF50 scores for paediatric PAH
patients at inclusion and last assessment (n = 19) versus stan-
dard (n = 73) and asthmatic (n = 74) paediatric reference cohorts.
GH, general health perceptions; PF, physical functioning; REB,
role/social limitations: emotional/behavioral; RP, role/social lim-
itations: physical; BP, bodily pain/discomfort; BE, behaviour MH,
F
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amental health; SE, self-esteem; PE, parent impact emotion; PT,
parent impact time; FA, family activities; FC, family cohesion.
reference cohorts although behaviour and familial cohesion
were preserved (Fig. 1). At the last assessment (n = 19),
the scores were not statistically different except for bodily
pain (p = 0.02) and mental health (p = 0.03), which both
improved.
Survival
Kaplan-Meyer estimates of survival at one and two years
were 86% (95% CI 76, 96) and 82% (95% CI 71, 93) (Fig. 2),
respectively. Nine patients died during study period. Of
these, four (44%) had PAH in conjunction with CHD, two
(22%) had IPAH and one (11%) had familial PAH. Of the nine
deaths, four resulted from clinical progression of PAH, two
D
T
o
Table 4 Changes in treatments.
Parameter Inclusion
No PAH-speciﬁc treatmenta 9 (18)
Monotherapya 30 (60)
Bitherapya 9 (18)
Tritherapya 2 (4)
Bosentan 38 (76)
Epoprostenol 12 (24)
Iloprost 2 (4)
Sildenaﬁl 3 (6)
Calcium channel blocker 6 (12)
Anticoagulant 10 (20)
Values are number (percentage) of patients.
a Bosentan, epoprostenol, iloprost and/or sildenaﬁl.igure 2. Kaplan—Meier survival estimates.
rom heart failure, two from sudden death and one from
ulmonary disease.
reatment
onotherapy with a PAH-speciﬁc treatment was less fre-
uent at the last assessment than at inclusion. Conversely,
itherapy and tritherapy were increased (Table 4). Bosentan
as the most frequently prescribed PAH-speciﬁc treatment
t inclusion and last assessment, and sildenaﬁl was the
ost frequently added treatment between inclusion and last
ssessment.iscussion
his multicentre study investigated the epidemiology and
utcome of PAH in the French paediatric population treated
(n = 50) Last assessment (n = 50)
11 (22)
17 (34)
16 (32)
6 (12)
39 (78)
10 (20)
2 (4)
17 (34)
5 (10)
10 (20)
7w
n
t
t
i
t
d
t
p
p
P
T
t
b
3
I
r
b
m
c
[
C
P
P
a
a
n
T
c
a
a
P
t
c
c
d
v
e
s
I
s
c
t
i
t
d
i
e
p
i
P
h
d
m
a
H
w
h
o
w
t
Q
A
l
C
c
t
o
[
c
N
i
a
m
F
W
e
a
m
t
n
o
t
c
r
t
s
i
a
d
s
i
8
w
I
e
i
s
b
[
I
r
y
e
n
p
p
T2
ith the strategies developed for adults with IPAH [8]. Until
ow, few studies have described the course of this devas-
ating disease in children and they have been limited by
he inclusion of small numbers of patients or from hav-
ng been conducted before the availability of PAH-speciﬁc
herapies [3,20,21]. The present registry was initiated to
escribe the French paediatric PAH population in the current
reatment era when several disease-speciﬁc therapies (e.g.,
rostacyclin, endothelin receptor antagonists, and type 5
hosphodiesterase inhibitors) are commercially available.
revalence
he overall prevalence for paediatric PAH (excluding persis-
ent pulmonary hypertension of the newborn and PAH caused
y CHD) in France, in 2005, was estimated to be at least
.7 cases per million and at least 2.2 cases per million for
PAH. The referral centres that participated to the study rep-
esent the majority of large University Hospitals in France
ut these numbers should be regarded as slight underesti-
ates of the true prevalence. The prevalence of IPAH in
hildren was the same as that reported in the adult registry
4].
linical presentation
aediatric PAH has a distinct proﬁle compared with adult
AH [4]. In children, idiopathic / familial PAH and PAH-CHD
ccount for the majority of the PAH cases. There are fewer
ssociations between PAH and portal hypertension or con-
ective tissue disease in paediatric versus adult patients.
hese differences may result from dissimilar underlying
auses of PAH in adult patients, such as PAH resulting from
norexigen intake, or the longer durations of illness associ-
ted with portopulmonary hypertension.
Twelve patients (24%) fulﬁlled the inclusion criteria of
AH in conjunction with CHD. Half of these patients had a
ransposition of the great arteries or scimitar syndrome, two
onditions that have been previously reported to occur in
onjunction with PAH [22,23]. The other half had a patent
uctus arteriosus or atrial septal defect but the pulmonary
ascular resistance increase was considered to occur too
arly in life to be related to the natural course of the
hunt. These patients were therefore considered to have
PAH-like PAH occurring in conjunction with CHD and repre-
ent a different population of patients than those having PAH
aused by chronic left-to-right shunts or left heart obstruc-
ion defects.
At inclusion, the majority of patients recorded in this reg-
stry were in WHO functional class II or III (71%). Although
his classiﬁcation can be difﬁcult to apply in young chil-
ren, it suggests an earlier diagnosis than for the adults
ncluded in the French registry [4]. These patients had an
levated pulmonary pressure but their cardiac index was
reserved; they had no signs of right heart failure, which
s a frequently observed difference with adult patients with
AH [21,24]. Children seem to tolerate the increased right
eart workload better than adults for the same degree of
isease severity. The children from this cohort were also
ore likely to respond to acute vasodilator testing than the
dults included in the French registry (11% versus 5.8%) [4].
owever, there is a wide variability in paediatric patients
t
e
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t
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ith numbers of responders to acute vasodilator testing as
igh as 40% [25]. Most patients with PAH, whether adults
r children, will lose their initial acute vasoresponsiveness
ithin several years and need PAH-speciﬁc therapy before
hey begin to deteriorate [26].
uality of life
lthough the assessment of quality of life in children is
ess straightforward than in adults, the parent administered
HQ-PF50 is considered a valid and reliable instrument for
hildren aged over ﬁve years [15]. The CHQ-PF50 scores from
his cohort indicate that paediatric PAH patients have a low
verall quality of life in comparison with healthy children
16] and children with asthma [17], even though familial
ohesion is preserved as seen for many chronic diseases [27].
evertheless, the overall quality of life was maintained dur-
ng the study and some scores even improved (mental health
nd bodily pain). The majority (81%) of this cohort attended
ainstream school at inclusion and last follow-up.
ollow-up and survival
ith the development of continuous intravenous
poprostenol in the late 1980s and the more recent
vailability of bosentan, sildenaﬁl and iloprost, the treat-
ent of children with PAH has considerably evolved in
he past few years [24,26,28,29]. Whilst the study was
on-interventional, it was observed that a high proportion
f patients received targeted therapies for PAH, despite
he absence of controlled trials supporting their use in
hildren. Moreover during the 2-year follow-up, patients
eceived an increasing number of combined PAH-speciﬁc
herapies, which may have contributed to their relative
tability regarding clinical status (73% patients presented
mprovement or no change in functional class), 6MWD,
nd quality of life. Given the appalling prognosis of this
isease, it is encouraging that children presented signs of
tabilization or improvement, even at the expense of an
ncrease in medication. The observed survival estimates,
6% at one year and 82% at two years, compare favourably
ith the median survival of 10 months reported by National
nstitutes of Health registry in 1991 [3] or with survival
stimates of 37% at one year and 12% at 2.5 years observed
n a Canadian study [20], before the availability of PAH-
peciﬁc therapies. Survival as high as 88% at two years with
osentan [24] and 88% at three years with epoprostenol
26] have subsequently been reported for children with
PAH. Our survival ﬁgures are very similar to those recently
eported by Haworth et al. (86% and 80% at one and three
ears, respectively) for children with IPAH treated with
poprostenol, sildenaﬁl and/or bosentan [30].
The study ﬁndings suggest that an increasing aware-
ess of novel therapeutic options for adolescent and adult
atients with PAH may have inﬂuenced the decisions of
hysicians faced with the management of paediatric PAH.
he concept of starting treatment with a single PAH-speciﬁc
herapy, followed by combination therapy has shown ben-
ﬁt in adult trials as well as in a recent paediatric study
30]. This highlights the need for continued evaluation of
he treatment of paediatric patients with PAH, to enable
linicians to make informed treatment decisions.
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Limitations
This study was limited by its observational design resulting
in the inclusion of children with long-term ongoing disease
and children newly diagnosed. A second limitation is the lack
of right heart catheterization in seven patients at diagnosis
and 37 patients at the last assessment. Finally, the CHQ-PF50
questionnaire could only be used in those children older than
ﬁve years and this instrument, which is not speciﬁc for PAH,
may have limited sensitivity in detecting changes in quality
of life resulting from PAH progression/treatment over time.
Conclusion
In children, idiopathic / familial PAH and PAH-CHD account
for the majority of PAH cases. The present registry provides
an overview of the current state of care and management
of paediatric PAH in France and supports the use in children
of the PAH-speciﬁc treatments that have been developed
for adults. In addition, we suggest that a particular group
of patients with PAH in conjunction with CHD can be iden-
tiﬁed who are more likely to show signs similar to those
of IPAH patients than those who have developed PAH as a
consequence of a CHD.
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